Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Fundamental Analysis

NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD

104.96  -0.05 (-0.05%)

Fundamental Rating

3

VRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. While VRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. VRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRNA had negative earnings in the past year.
In the past year VRNA has reported a negative cash flow from operations.
In the past 5 years VRNA always reported negative net income.
In the past 5 years VRNA always reported negative operating cash flow.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VRNA (-31.17%) is comparable to the rest of the industry.
With a Return On Equity value of -72.35%, VRNA perfoms like the industry average, outperforming 45.88% of the companies in the same industry.
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROIC N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 33.49%, VRNA is in line with its industry, outperforming 57.73% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VRNA has more shares outstanding
The debt/assets ratio for VRNA is higher compared to a year ago.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

VRNA has an Altman-Z score of 16.73. This indicates that VRNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VRNA (16.73) is better than 89.69% of its industry peers.
VRNA has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
VRNA has a worse Debt to Equity ratio (1.07) than 71.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z 16.73
ROIC/WACCN/A
WACC9.17%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

VRNA has a Current Ratio of 8.86. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VRNA (8.86) is better than 79.90% of its industry peers.
A Quick Ratio of 8.73 indicates that VRNA has no problem at all paying its short term obligations.
The Quick ratio of VRNA (8.73) is better than 79.90% of its industry peers.
Industry RankSector Rank
Current Ratio 8.86
Quick Ratio 8.73
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VRNA have decreased strongly by -163.16% in the last year.
VRNA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.86% yearly.
EPS 1Y (TTM)-163.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.15% on average over the next years. This is quite good.
VRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.46% yearly.
EPS Next Y109.68%
EPS Next 2Y64.68%
EPS Next 3Y50.65%
EPS Next 5Y19.15%
Revenue Next Year991.17%
Revenue Next 2Y335.44%
Revenue Next 3Y199.73%
Revenue Next 5Y123.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

VRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
VRNA is valuated quite expensively with a Price/Forward Earnings ratio of 68.26.
Based on the Price/Forward Earnings ratio, VRNA is valued a bit cheaper than 67.53% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VRNA to the average of the S&P500 Index (36.71), we can say VRNA is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 68.26
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

VRNA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as VRNA's earnings are expected to grow with 50.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.68%
EPS Next 3Y50.65%

More info and screens

0

5. Dividend

5.1 Amount

VRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (7/23/2025, 3:30:05 PM)

104.96

-0.05 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners74.02%
Inst Owner Change-0.19%
Ins Owners10.87%
Ins Owner Change-2.88%
Market Cap8.92B
Analysts85.56
Price Target108.43 (3.31%)
Short Float %10.93%
Short Ratio2.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.32%
Min EPS beat(2)-34.07%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-60.23%
Min EPS beat(4)-192.46%
Max EPS beat(4)-4.58%
EPS beat(8)3
Avg EPS beat(8)-23.74%
EPS beat(12)4
Avg EPS beat(12)-23.95%
EPS beat(16)8
Avg EPS beat(16)-6.04%
Revenue beat(2)2
Avg Revenue beat(2)24.41%
Min Revenue beat(2)8.73%
Max Revenue beat(2)40.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.23%
PT rev (3m)32.32%
EPS NQ rev (1m)1097.6%
EPS NQ rev (3m)157.14%
EPS NY rev (1m)310%
EPS NY rev (3m)-28.32%
Revenue NQ rev (1m)1.1%
Revenue NQ rev (3m)36.83%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)31.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 68.26
P/S 75.28
P/FCF N/A
P/OCF N/A
P/B 39.38
P/tB 39.48
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)1.54
Fwd EY1.46%
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS1.39
BVpS2.67
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.49%
FCFM N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.83%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.86
Quick Ratio 8.73
Altman-Z 16.73
F-Score2
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y109.68%
EPS Next 2Y64.68%
EPS Next 3Y50.65%
EPS Next 5Y19.15%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year991.17%
Revenue Next 2Y335.44%
Revenue Next 3Y199.73%
Revenue Next 5Y123.46%
EBIT growth 1Y-89.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.58%
EBIT Next 3Y91.37%
EBIT Next 5YN/A
FCF growth 1Y-137.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135%
OCF growth 3YN/A
OCF growth 5YN/A